Medmen: Canaccord Raises Price Target, Rating After Q4 Performance

On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth-quarter financial results. The company reported revenue of $42 million, up 18.5% quarter over quarter and 55.4% year over year. The company saw gross margins come in at 46.9%, up from 40.5% last quarter.

After the results, Canaccord Genuity raised their 12-month price target from C$0.40, while also giving Medmen a hold rating, an improvement from their previous sell rating. They say that the combination of Tilray’s debt extension and the $100 million equity financing, on top of a revenue beat, was the reason for the upgrade and price target raise.

Medmen beat on most of Canaccord’s key estimates. Canaccord forecasted fourth quarter revenue to be $34.5 million, with adjusted EBITDA coming in at ($10.7) million. Canaccord says that the majority of the beat comes from a rebound in California, Medmen’s core market.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Medmen’s California segment grew 24.4% quarter over quarter. Canaccord says that the companies increased gross margins are “a result of increased operating leverage at the company’s remaining cultivation/manufacturing facilities.”

Canaccord re-touches on the Tilray and $100 million investment, saying that everyone was a winner in the transaction. Tilray now has a path to the US cannabis sector and Medmen has a reduced near-term interest and debt burden. They write, “After updating our model for a slightly reduced risk profile in CA and factoring in the company’s recent debt assumption from Tilray as well as its subsequent ~$100M equity financing, we believe the company’s turnaround prospects continue to improve.”

Below you can see Canaccord’s updated fiscal 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Cresco Labs Announces At-The-Market Offering Amid Share Unlock

Cresco Labs (CSE: CL) this morning announced an at-the-market offering, also known as an ATM,...

Tuesday, December 3, 2019, 08:57:21 AM

Cameco: Canaccord Anticipates Mixed Results For Q2 2022

Cameco (TSX: CCO) is expected to report its second quarter financial results on July 27...

Monday, July 25, 2022, 04:47:00 PM

WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL)...

Friday, October 23, 2020, 01:37:00 PM

CN Rail: BMO Resumes Coverage With $155 Price Target

A number of analysts changed their recommendations and price targets on Canadian National Railway (TSX:...

Sunday, September 26, 2021, 01:38:00 PM

Alamos Gold Sees Canaccord Lift Rating To Buy After Q1 Results

This past week Alamos Gold Inc. (TSX: AGI) reported its first quarter financial results. The...

Saturday, April 30, 2022, 01:16:00 PM